|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 321.15 DKK | +0.45% |
|
+3.73% | -48.55% |
| 12-13 | Sector Update: Health Care Stocks Advance Late Afternoon | MT |
| 12-12 | Sector Update: Health Care Stocks Edge Higher Friday Afternoon | MT |
| Capitalization | 1,427B 224B 191B 178B 168B 309B 20,308B 338B 2,083B 808B 9,573B 841B 824B 34,925B | P/E ratio 2025 * |
13.9x | P/E ratio 2026 * | 14x |
|---|---|---|---|---|---|
| Enterprise value | 1,531B 241B 205B 191B 180B 332B 21,792B 362B 2,235B 867B 10,272B 903B 884B 37,478B | EV / Sales 2025 * |
4.98x | EV / Sales 2026 * | 5x |
| Free-Float |
70.25% | Yield 2025 * |
3.62% | Yield 2026 * | 3.55% |
Last Transcript: Novo Nordisk A/S
| 1 day | +0.45% | ||
| 1 week | +3.73% | ||
| Current month | +1.31% | ||
| 1 month | +3.25% | ||
| 3 months | -7.80% | ||
| 6 months | -37.79% | ||
| Current year | -48.55% |
| 1 week | 295.5 |  | 325.4 |
| 1 month | 266.9 | | 325.4 |
| Current year | 266.9 | | 675.2 |
| 1 year | 266.9 | | 782.2 |
| 3 years | 266.9 | | 1,033.2 |
| 5 years | 208.78 | | 1,033.2 |
| 10 years | 109.1 | | 1,033.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 07/08/2025 | |
| Director of Finance/CFO | 54 | 15/02/2018 | |
Martin Lange
CTO | Chief Tech/Sci/R&D Officer | 55 | 07/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kasim Kutay
BRD | Director/Board Member | 60 | 23/03/2017 |
| Director/Board Member | 50 | 22/03/2018 | |
Thomas Rantzau
BRD | Director/Board Member | 53 | 22/03/2018 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 21.31% | 1,412 M€ | +0.89% | - |
| 10.45% | 4 M€ | +21.49% | - |
| 5.4% | 26 M€ | +11.37% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.45% | +3.73% | -57.41% | -31.49% | 224B | |
| +1.80% | +1.70% | +30.21% | +182.67% | 920B | |
| +0.75% | +4.78% | +44.31% | +17.70% | 510B | |
| -0.29% | -1.22% | +28.81% | +35.46% | 395B | |
| -0.35% | +1.90% | +25.12% | +3.01% | 340B | |
| -1.12% | -1.09% | +28.43% | +17.93% | 278B | |
| -0.45% | -1.48% | +20.24% | +22.49% | 254B | |
| +1.30% | +0.58% | -1.67% | -10.09% | 249B | |
| +0.11% | -3.68% | +17.41% | +17.19% | 171B | |
| -2.28% | -0.68% | +31.08% | +36.20% | 149B | |
| Average | -0.01% | +0.45% | +16.65% | +29.11% | 349.14B | |
| Weighted average by Cap. | +0.42% | +1.07% | +22.26% | +57.74% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 308B 48.33B 41.17B 38.46B 36.19B 66.62B 4,377B 72.78B 449B 174B 2,063B 181B 178B 7,528B | 305B 48B 40.89B 38.19B 35.94B 66.16B 4,347B 72.28B 446B 173B 2,049B 180B 176B 7,476B |
| Net income | 103B 16.14B 13.75B 12.84B 12.08B 22.25B 1,462B 24.3B 150B 58.15B 689B 60.56B 59.28B 2,514B | 99.65B 15.66B 13.34B 12.46B 11.72B 21.58B 1,418B 23.58B 145B 56.41B 668B 58.75B 57.51B 2,439B |
| Net Debt | 104B 16.39B 13.96B 13.04B 12.27B 22.59B 1,484B 24.67B 152B 59.04B 700B 61.48B 60.19B 2,552B | 99.59B 15.65B 13.33B 12.45B 11.72B 21.57B 1,417B 23.56B 145B 56.38B 668B 58.71B 57.48B 2,437B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 321.15 kr | +0.45% | 6,447,389 |
| 11/12/25 | 319.70 kr | +3.43% | 7,866,315 |
| 10/12/25 | 309.10 kr | +3.31% | 5,688,570 |
| 09/12/25 | 299.20 kr | +0.07% | 4,792,858 |
| 08/12/25 | 299.00 kr | -3.42% | 5,643,749 |
Delayed Quote Nasdaq Copenhagen, December 12, 2025 at 08:20 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition